Sign In
Buy KROS
$11.15
+0.500 (+4.69%)
At Close: Aug 07, 2026
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
08:00am, Wednesday, 28'th Aug 2024
LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics Reports Second Quarter 2024 Financial Results
04:01pm, Wednesday, 07'th Aug 2024
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
02:43pm, Tuesday, 25'th Jun 2024
Oppenheimer initiated coverage on Keros Therapeutics Inc KROS, a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics for disorders linked to dysfunctional sign
Keros Therapeutics Announces Leadership Updates
04:01pm, Monday, 17'th Jun 2024
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, develop
LEXINGTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers
12:48pm, Monday, 10'th Jun 2024
Five Keros Therapeutics, Inc. abstracts are expected at the upcoming EHA conference between June 13th -16th of 2024, showcasing data using KER-050 for the treatment of patients with low-risk myelodysp
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
04:01pm, Tuesday, 28'th May 2024
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and comm
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
10:00am, Tuesday, 14'th May 2024
LEXINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel the
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
08:00am, Wednesday, 08'th May 2024
LEXINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and comm
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
08:00am, Tuesday, 05'th Mar 2024
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel t
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
04:01pm, Wednesday, 28'th Feb 2024
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and com
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Wednesday, 28'th Feb 2024
Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that mad
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
10:56am, Wednesday, 21'st Feb 2024
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 35.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
09:51am, Monday, 12'th Feb 2024
Keros Therapeutics, Inc. (KROS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
10:56am, Wednesday, 31'st Jan 2024
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme
